AI-generated · cited to primary sources · not investment advice
ERIS Lifescience (540596) May 2025 Filing Analysis
Does management do what it says?
Management has decided to cancel the launch of gSaxenda due to delays in regulatory approval. (2 dropped, 1 revised, 1 in progress across 4 tracked commitments)
“gSaxenda – the first Generic launch in India for Obesity – we are targeting a Q1-FY26 launch”
Revenue opportunity from Human Insulin cartridges market disruption — target: Rs. 200 crores to Rs. 300 crores per annum
“We believe that we can take Rs. 200 crores to Rs. 300 crores per annum of this opportunity starting the second half of this financial year.”
See the full cited Management analysis of ERIS Lifescience
How durable is the business?
The company is shifting back to in-house manufacturing to reclaim margins lost during recent acquisitions, targeting over 80% in-house production by Q4 FY26. (1 shifted, 3 expanding)
“We expect to get back to ~ 80% inhouse production by Q4 FY26... This will result in three key benefits: Higher margin”
See the full cited Business Model analysis of ERIS Lifescience
What could break the thesis?
The risk is easing as the company is aggressively in-sourcing production. In-house production rose from <50% in April '24 to 66% in March '25, with a target of 80% by year-end to drive margin expansion. (1 easing)
“The in-house production stood at 66% as of March and by the end of Q4 of this year, we'll be back at 80%.”
See the full cited Risk analysis of ERIS Lifescience
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.